Skip to search.

Breaking News Visit Yahoo! News for the latest.

×Close this window

 Dow Up0.22% Nasdaq Up0.24%

Amicus Therapeutics, Inc. (FOLD)

-NasdaqGM

3.45 Up 0.02(0.55%) 12:12PM EDT - Nasdaq Real Time Price

Add to Portfolio
ProfileGet Profile for:
Amicus Therapeutics, Inc.
1 Cedar Brook Drive
Cranbury, NJ 08512
United States - Map
Phone: 609-662-2000
Fax: 609-662-2001
Website: http://www.amicustherapeutics.com

Details 
Index Membership:N/A
Sector:Healthcare
Industry:Biotechnology
Full Time Employees:112

Business Summary 

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs known as pharmacological chaperones. It develops pharmacological chaperones as next-generation medicines for a range of rare and orphan diseases with a focus on improved therapies for lysosomal storage disorders. The company’s development programs include small molecules as monotherapy treatments for Fabry and other lysosomal storage diseases, and enzyme replacement therapy (ERT). Its chaperone-advanced replacement therapy programs comprise chaperones co-administered with currently marketed ERTs, as well as proprietary therapeutic enzymes co-formulated with pharmacological chaperones as next-generation ERTs. The company’s primary product includes migalastat HCl, a product candidate for Fabry disease that is in Phase III global registration studies for patients with genetic mutations. Its products also comprise AT2220, which has completed Phase II safety used for the treatment of Pompe disease; and AT3375 and afegostat tartrate that are in preclinical studies used for treating Gaucher disease. The company has strategic collaboration with GlaxoSmithKline PLC to develop and commercialize migalastat HCl. Amicus Therapeutics, Inc. was founded in 2002 and is based in Cranbury, New Jersey.

Key Statistics


Company Websites 
Home Page
Search Yahoo! for:
More on Amicus Therapeutics, Inc.

Corporate Governance 
Amicus Therapeutics, Inc.’s ISS Governance QuickScore as of May 1, 2013 is 8. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 7; Compensation: 10.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
 PayExercised
Mr. John F. Crowley , 45
Chairman and Chief Exec. officer
N/AN/A
Mr. William D. Baird III, 41
Chief Financial Officer
386.00K0.00
Ms. Daphne E. Quimi , 47
Principal Accounting Officer and Corp. Controller
260.00K0.00
Dr. David J. Lockhart Ph.D., 51
Chief Scientific Officer
539.00K0.00
Mr. Bradley L. Campbell , 37
Chief Bus. Officer
472.00K0.00
Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders